Patrick J. Stiff
Distinguished in Hodgkin Lymphoma

Dr. Patrick J. Stiff

Hematology Oncology | Hematology | Oncology
Loyola University Medical Center
2160 S 1st Ave, 
Maywood, IL 
 (972 mi)
Accepting New Patients
45 Years of Experience
Distinguished in Hodgkin Lymphoma
Loyola University Medical Center
2160 S 1st Ave, 
Maywood, IL 
 (972 mi)
OverviewInsuranceLocationsClinical Research

Overview

Patrick Stiff is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Stiff has been practicing medicine for over 45 years and is rated as a Distinguished provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Stiff is currently accepting new patients.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles and participated in 2 clinical trials in the study of Hodgkin Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
Loyola University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Oscar
  •  Humana

Locations

LOYOLA UNIVERSITY MEDICAL CENTER
2160 S 1st Ave, Maywood, IL 60153
Other Locations
LOYOLA UNIVERSITY MEDICAL CENTER
5340 Holy Cross Pkwy, Mishawaka, IN 46545

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
Study Phase: Phase 2
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug, Biological
Study Drugs: KTE-X19 Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 1/Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Genetic
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Safety, Efficacy and Feasibility of Haploidentical Stem Cell Transplantation (Haplo-SCT) Using Post-Transplant Cyclophosphamide (PTCy) as an Alternative Donor Source for Patients Who Lack a Matched Sibling/Unrelated Donor Options
Safety, Efficacy and Feasibility of Haploidentical Stem Cell Transplantation (Haplo-SCT) Using Post-Transplant Cyclophosphamide (PTCy) as an Alternative Donor Source for Patients Who Lack a Matched Sibling/Unrelated Donor Options
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug, Other
Study Drugs: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Study Phase: Phase 2
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: February 22, 2023
Intervention Type: Drug
Study Drugs: I-131-CLR1404, Dexamethasone
Study Phase: Phase 1
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Suspended
Publish Date: January 25, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 27, 2018
Intervention Type: Biological
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

112 Total Publications

Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 19, 2024
Similar Doctors
Elite in Hodgkin Lymphoma
Dr. Leo I. Gordon
Hematology Oncology | Oncology | Hematology
Elite in Hodgkin Lymphoma
Dr. Leo I. Gordon
Hematology Oncology | Oncology | Hematology

Northwestern Medical Faculty Foundation

676 N Saint Clair St, Suite 850, 
Chicago, IL 
 (11.2 mi)
312-695-6180
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Gordon is a Hematologist Oncology specialist and an Oncologist in Chicago, Illinois. Dr. Gordon and is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is currently accepting new patients.

Elite in Hodgkin Lymphoma
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology
Elite in Hodgkin Lymphoma
Dr. Sonali M. Smith
Hematology Oncology | Hematology | Oncology

University Of Chicago

355 E Grand Ave, 
Chicago, IL 
 (11.4 mi)
888-824-0200
Languages Spoken:
English, Greek, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Smith and is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is currently accepting new patients.

Reem M. Karmali
Elite in Hodgkin Lymphoma
Dr. Reem M. Karmali
Hematology Oncology | Hematology | Oncology
Elite in Hodgkin Lymphoma
Dr. Reem M. Karmali
Hematology Oncology | Hematology | Oncology

Northwestern Medical Faculty Foundation

250 E Superior St, 
Chicago, IL 
 (11.3 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Reem Karmali is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Karmali and is rated as an Elite provider by MediFind in the treatment of Hodgkin Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Karmali is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile